ELEDON PHARMACEUTICALS INC (ELDN)
Health Care · Clinical-stage biopharmaceuticals · NASDAQ
Eledon is a clinical-stage biopharmaceutical company developing tegoprubart and other drug candidates to address serious diseases.
What ELEDON PHARMACEUTICALS INC does
Eledon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel drug candidates to treat serious diseases. The company's primary efforts have been devoted to advancing tegoprubart through preclinical and clinical development, with no approved products for commercial sale to date. Eledon is in the early stages of clinical development and has financed its operations primarily through sales of equity securities, with all resources focused on research and development activities.
Themes: ["drug development","clinical trials","biotech R&D"]
Fundamentals
- Price$4.13 as of 2026-07-09 close
- Market cap$319M as of 2026-07-10
- 1-year return+21.5% as of 2026-07-09 close
- ROE-72.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta0.98 as of 2026-07-10
Key risks (from latest filing)
["Clinical-stage company with no approved products and no revenue from product sales; tegoprubart and future candidates may not be successfully developed or approved for commercialization","Significant ongoing losses and negative cash flows since inception; accumulated deficit of $440.2 million as of Q1 2026 with no path to profitability established","Dependence on raising additional capital to fund drug development, manufacturing, regulatory approvals, and commercialization; equity dilution from ongoing fundraising and warrant exercises"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.